Clinical Trial Update: Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome [Phase 1]

View source ↗

Summary

Phase 1 study evaluating TNX-832 (Sunol cH36) in subjects with sepsis-associated acute lung injury and acute respiratory distress syndrome has completed enrollm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome
• Sepsis

Drugs mentioned

• TNX-832 (Sunol cH36) (TNX-832)

Snippet

Sponsor: Altor BioScience | Conditions: Sepsis, Acute Lung Injury | Phase 1 | Status: COMPLETED | Results posted: 2025-01-06